148 related articles for article (PubMed ID: 22628228)
1. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
Dasgupta A; Johnson MJ; Sengupta TK
J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
[TBL] [Abstract][Full Text] [Related]
2. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
Dasgupta A; Johnson MJ
J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
[TBL] [Abstract][Full Text] [Related]
3. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
[TBL] [Abstract][Full Text] [Related]
4. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
Datta P; Dasgupta A
Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
[TBL] [Abstract][Full Text] [Related]
5. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
Dasgupta A; Tso G; Wells A
Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
[TBL] [Abstract][Full Text] [Related]
6. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
Dasgupta A; Kang E; Datta P
J Clin Lab Anal; 2006; 20(5):204-8. PubMed ID: 16960898
[TBL] [Abstract][Full Text] [Related]
7. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.
Dasgupta A; Saffer H; Wells A; Datta P
J Clin Lab Anal; 2002; 16(4):172-7. PubMed ID: 12112389
[TBL] [Abstract][Full Text] [Related]
8. The new LOCI digoxin assay on the Vista 1500 analyzer is virtually free from interferences of herbal supplements hawthorn and ashwagandha (Indian ginseng).
Dasgupta A; Johnson MJ; Wahed A
J Clin Lab Anal; 2012 Jul; 26(4):227-31. PubMed ID: 22811353
[TBL] [Abstract][Full Text] [Related]
9. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
Steimer W; Müller C; Eber B
Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
[TBL] [Abstract][Full Text] [Related]
10. Effect of Chinese medicines Chan Su, Asian ginseng, Siberian ginseng, and American ginseng on a new digoxin immunoassay based on luminescent oxygen channeling technology.
Dasgupta A; Syklawer E; Johnson M; Hwang SA; Boyd SA; Actor JK
Ther Drug Monit; 2011 Oct; 33(5):644-8. PubMed ID: 21860344
[TBL] [Abstract][Full Text] [Related]
11. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
Foukaridis GN
Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
[TBL] [Abstract][Full Text] [Related]
12. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
Pleasants RA; Williams DM; Porter RS; Gadsden RH
Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
[TBL] [Abstract][Full Text] [Related]
13. Intoxication due to negative canrenone interference in digoxin drug monitoring.
Steimer W; Müller C; Eber B; Emmanuilidis K
Lancet; 1999 Oct; 354(9185):1176-7. PubMed ID: 10513714
[TBL] [Abstract][Full Text] [Related]
14. Bidirectional (negative/positive) interference of oleandrin and oleander extract on a relatively new Loci digoxin assay using Vista 1500 analyzer.
Dasgupta A; Welsh KJ; Hwang SA; Johnson M; Actor JK
J Clin Lab Anal; 2014 Jan; 28(1):16-20. PubMed ID: 24375780
[TBL] [Abstract][Full Text] [Related]
15. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone and potassium canrenoate in normal man.
Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone metabolite causes falsely increased progesterone in the Abbott Architect immunoassay.
Sarpong KAN; Hee Kim S; McCartney CR; Wiencek JR; Bazydlo LAL
Clin Biochem; 2024 Apr; 126():110747. PubMed ID: 38484829
[TBL] [Abstract][Full Text] [Related]
18. Canrenone--the principal active metabolite of spironolactone?
Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
[TBL] [Abstract][Full Text] [Related]
19. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: an assessment.
Cobo A; Martín-Suarez A; Calvo MV; Domínguez-Gil A; de Gatta MM
Ther Drug Monit; 2010 Apr; 32(2):169-76. PubMed ID: 20216123
[TBL] [Abstract][Full Text] [Related]
20. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
Lichey J; Schröder R; Rietbrock N
Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
